Clinical Trials Logo

Coronary Heart Disease clinical trials

View clinical trials related to Coronary Heart Disease.

Filter by:

NCT ID: NCT06253481 Recruiting - Atrial Fibrillation Clinical Trials

Genetics of Cardiovascular Disease

GCVD
Start date: November 24, 2021
Phase:
Study type: Observational

Participants are being recruited at the inpatient department of the National Medical Research Center of Cardiology on a 'all-comers' basis. The enrolled participants will be divided into the main group (diagnosed with atherosclerotic cardiovascular disease (ASCVD)) and control (not diagnosed with ASCVD). The participants will have whole blood and serum collected at enrollment for further biobanking. A genome-wide association study will be carried out to determine the genetic determinants associated with atherosclerosis, coronary heart disease, acute coronary syndrome, etc., including a search for pathogenic variants.

NCT ID: NCT06226948 Not yet recruiting - Clinical trials for Coronary Artery Disease

Using the Visualization for Lifestyle Change in Patients at Risk of Cardiovascular Diseases

Start date: March 2024
Phase: N/A
Study type: Interventional

In the framework of PhD research, we will present a visualization of estimation of CVDs risk and the possibility of monitoring blood glucose levels in real-time. Based on the results, we will assess the association of these with lifestyle change. The findings highlight the need for sufficiently reliable and high-quality evaluations of visualizations, technologies or applications used in the family medicine.

NCT ID: NCT06214624 Enrolling by invitation - Clinical trials for Coronary Heart Disease

Exercise and Brain in Coronary Heart Disease

Heart-Brain
Start date: April 19, 2022
Phase: N/A
Study type: Interventional

The Heart-Brain project is a randomized controlled trial designed to examine the effects of two different exercise programs of 12-week duration: 1) aerobic high intensity interval training (HIIT), and 2) aerobic HIIT plus resistance training, on brain health and other outcomes in coronary heart disease patients.

NCT ID: NCT06190834 Recruiting - Clinical trials for Coronary Heart Disease

Relationship Between High-Density Lipoprotein Subtypes and Coronary Heart Disease Prognosis.

RHDLS-CHD
Start date: December 1, 2023
Phase:
Study type: Observational

Cardiovascular disease (CVD) is the leading cause of human mortality worldwide, imposing substantial societal and economic burdens. Traditionally, high-density lipoprotein (HDL) has been branded as the "beneficial" lipoprotein. The Framingham study found that for every 1mg/dl increase in HDL, the risk of coronary heart disease (CHD) was reduced by 2% in men and 3% in women. Subsequent studies further affirmed the inverse correlation between HDL and the risk of CHD. However, these findings were first challenged by Mendelian randomization studies which failed to identify a causal relationship between HDL and CHD. Moreover, randomized controlled trials demonstrated that therapeutically increasing plasma HDL concentrations did not reduce the risk of CHD events, prompting doubts about HDL's status as "good cholesterol." The relationship between HDL and CHD might be more intricate than previously believed, possibly not just mediated by the quantity of HDL but also intimately linked with its function. Several cross-sectional studies have confirmed the relationship between HDL subtypes and the severity of disease in CHD patients, yet findings are inconsistent. Conventional testing methods lack a universally accepted standard for defining or describing HDL subfractions, with issues like expensive equipment, poor repeatability, cumbersome operation, slow analysis, and low throughput. Microfluidic electrophoresis technology combines the merits of electrophoresis with microfluidic chip technology. This method facilitates efficient separation of substances in microchannels on a substrate, providing rapid and consistent results. Utilizing the latest microfluidic chip technology for HDL subfraction detection offers quick, accurate, and straightforward analysis with minimal sample volume and automation. It precisely reflects the serum concentrations of HDL subfractions HDL2b and HDL3, addressing the current pitfalls of clinical HDL subfraction analysis methods. This approach is poised to become the standard method for HDL subfraction testing. In conclusion, existing studies on the association between HDL subtypes and CHD remain inconsistent, with most having a small sample size. Our study, leveraging microfluidic chip technology for HDL subfraction detection, aims to further investigate: the prognostic value of HDL subtypes for the long-term outcomes of CHD patients, building a risk prediction model for adverse cardiovascular events that includes HDL subtypes.

NCT ID: NCT06178263 Completed - Clinical trials for Coronary Heart Disease

Adherence to an Exercise and Healthy Diet Program in Patients With Coronary Heart Disease Aged ≥ 60 Years

RE-Start60+
Start date: December 1, 2017
Phase:
Study type: Observational

The purpose of the study is to implement a multimodal lifestyle intervention over 3 months in individuals ≥ 60 years of age with coronary heart disease and to examine the adherence to this intervention program. The intervention focus on three main themes: physical activity, healthy nutrition and, if necessary, smoking. The framework is formed by a psychological component: views on ageing.

NCT ID: NCT06178133 Not yet recruiting - Clinical trials for Coronary Heart Disease

Influencing Factors of the Diagnostic Accuracy of Novel Coronary Functional Evaluation Methods

Start date: December 2023
Phase:
Study type: Observational

In this study, patients were retrospectively included, univariate and multivariate analysis of factors affecting their diagnosis inconsistencies was performed, and a new diagnostic model was constructed by logistic regression.

NCT ID: NCT06172985 Active, not recruiting - Clinical trials for Coronary Heart Disease

A CCTA Image Assisted Triage Software for the Assessment of Patients With Suspected Coronary Artery Disease

Start date: May 9, 2023
Phase:
Study type: Observational

The goal of this clinical trail is to evaluate the effectiveness and accuracy of the CCTA image assisted triage software(DeepVessel® Cardisight, Keya Medical.) for the triage of patients with suspected coronary artery disease.

NCT ID: NCT06168422 Recruiting - Clinical trials for Coronary Heart Disease

A Prospective Cohort Study of PCI Strategies for Severely Calcified Lesions of Complex Coronary Arteries in the Elderly

PSSCCE
Start date: December 25, 2023
Phase:
Study type: Observational

The aim of this observational study is to compare the prognostic outcomes of various PCI strategies in elderly patients with complex coronary calcified lesions. The patients will be classified into two groups and assigned different PCI strategies, either stenting or stenting combined with pharmacologic balloon implantation. The investigators will assess the one-year prognosis for major adverse cardiovascular events in these patients.

NCT ID: NCT06097663 Recruiting - Clinical trials for Coronary Heart Disease

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

Start date: February 16, 2024
Phase: Phase 2
Study type: Interventional

This Phase 2a clinical trial will evaluate the effectiveness, safety, and tolerability of increasing dose strengths of an oral daily medication, DFV890, administered for 12 weeks, or a single s.c. dose of MAS825, to reduce key markers of inflammation related to CVD risk, such as IL-6 and IL-18, in approximately 28 people with known coronary heart disease and TET2 or DNMT3A CHIP (VAF ≥2%).

NCT ID: NCT06091774 Recruiting - Clinical trials for Coronary Artery Disease

Clinical Study for the Investigation and Validation of a Therapy Procedure for the Adjustment of Risk Factors in Patients With Coronary Heart Disease by Means of Digital Therapy Control

ERKHA
Start date: October 5, 2023
Phase:
Study type: Observational

This study will test a controlled investigation of the efficacy and effectiveness of iATROS digital therapy management for risk factor adjustment in patients with coronary heart disease (CHD).